Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 4
1999 1
2006 1
2009 1
2014 1
2016 6
2017 411
2018 2846
2019 2894
2020 3463
2021 3658
2022 3483
2023 3484
2024 3556
2025 3655
2026 1640

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,467 results

Results by year

Filters applied: . Clear all
Page 1
Thalassemia.
Benz EJ Jr, Sankaran VG. Benz EJ Jr, et al. Hematol Oncol Clin North Am. 2023 Apr;37(2):xiii-xv. doi: 10.1016/j.hoc.2023.01.001. Hematol Oncol Clin North Am. 2023. PMID: 36907615 No abstract available.
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Merryman RW, et al. Blood Adv. 2020 Mar 10;4(5):858-867. doi: 10.1182/bloodadvances.2019001355. Blood Adv. 2020. PMID: 32126141 Free PMC article.
We conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of RB and 3 cycles of rituximab/high-dose cytarabine (RC) followed by autologous stem cell transplantation (ASCT) among untreated, transplant-eligible patients with MCL. Dana- …
We conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of RB and 3 cycles of rituximab/high-dose c …
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer.
Ricciuti B, Alessi JV, Elkrief A, Wang X, Cortellini A, Li YY, Vaz VR, Gupta H, Pecci F, Barrichello A, Lamberti G, Nguyen T, Lindsay J, Sharma B, Felt K, Rodig SJ, Nishino M, Sholl LM, Barbie DA, Negrao MV, Zhang J, Cherniack AD, Heymach JV, Meyerson M, Ambrogio C, Jänne PA, Arbour KC, Pinato DJ, Skoulidis F, Schoenfeld AJ, Awad MM, Luo J. Ricciuti B, et al. Ann Oncol. 2022 Oct;33(10):1029-1040. doi: 10.1016/j.annonc.2022.07.005. Epub 2022 Jul 22. Ann Oncol. 2022. PMID: 35872166 Free PMC article.
PATIENTS AND METHODS: Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial Coll …
PATIENTS AND METHODS: Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the …
The 2024 generation.
Aggarwal SS, Andreani C, Deng Z, Frede J, Kameneva P, Kovatcheva M, Micevic G, Nicolson F, Puschhof J, Roberts M, Wang G, Watson DC. Aggarwal SS, et al. Nat Cancer. 2024 Dec;5(12):1774-1778. doi: 10.1038/s43018-024-00866-2. Nat Cancer. 2024. PMID: 39690227 No abstract available.
Renal Cell Cancer.
McGregor BA, Choueiri TK. McGregor BA, et al. Hematol Oncol Clin North Am. 2023 Oct;37(5):xvii-xix. doi: 10.1016/j.hoc.2023.05.019. Epub 2023 Jun 15. Hematol Oncol Clin North Am. 2023. PMID: 37330344 No abstract available.
Preface.
Rubinson DA, Yurgelun MB. Rubinson DA, et al. Hematol Oncol Clin North Am. 2022 Oct;36(5):xiii-xiv. doi: 10.1016/j.hoc.2022.08.007. Hematol Oncol Clin North Am. 2022. PMID: 36265995 No abstract available.
Castleman Disease.
van Rhee F, Munshi NC. van Rhee F, et al. Hematol Oncol Clin North Am. 2018 Feb;32(1):xiii-xiv. doi: 10.1016/j.hoc.2017.10.001. Hematol Oncol Clin North Am. 2018. PMID: 29157623 No abstract available.
Preface.
Hodi FS. Hodi FS. Hematol Oncol Clin North Am. 2021 Feb;35(1):ix-x. doi: 10.1016/j.hoc.2020.09.006. Epub 2020 Oct 26. Hematol Oncol Clin North Am. 2021. PMID: 33759777 No abstract available.
Early Cancer Detection in Focus.
O'Donnell EK. O'Donnell EK. Hematol Oncol Clin North Am. 2024 Aug;38(4):xi-xii. doi: 10.1016/j.hoc.2024.04.006. Epub 2024 May 7. Hematol Oncol Clin North Am. 2024. PMID: 38719654 No abstract available.
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC.
Gandhi MM, Elkrief A, Moore CG, Ricciuti B, Alessi JV, Richards AL, Tischfield S, Williams J, Lamberti G, Pecci F, Di Federico A, Makarem M, Johnson BE, Nishino M, Sholl LM, Schoenfeld AJ, Awad MM. Gandhi MM, et al. J Thorac Oncol. 2025 Jun;20(6):725-738. doi: 10.1016/j.jtho.2025.01.016. Epub 2025 Jan 27. J Thorac Oncol. 2025. PMID: 39864548
METHODS: Clinicopathologic correlates of STK11, KEAP1, and SMARCA4 deletion were analyzed in cases of nonsquamous NSCLC at Dana-Farber Cancer Institute (DFCI). mRNA and LKB1 protein levels were assessed using The Cancer Genome Atlas. Clinical outcomes were an …
METHODS: Clinicopathologic correlates of STK11, KEAP1, and SMARCA4 deletion were analyzed in cases of nonsquamous NSCLC at Dana-Fa …
25,467 results
You have reached the last available page of results. Please see the User Guide for more information.